The Drug Annotations Series was launched in 2014 to share in case study form the story of a new drug from laboratory to clinical development. In Drug Annotations, readers follow the medicinal chemistry journey of an important drug that impacts human health. Our aim is to identify and publish these stories to instruct and support members of the chemistry and drug discovery communities in the pursuit of ground-breaking medicine for patients. Since its inception, the Drug Annotations Series has become the premier venue to showcase such case studies. As of this writing, 55 manuscripts have been published and the manuscripts have spanned a range of modalities including small molecules, proteins, and antibody drug conjugates, just to name a few. We would like to take this opportunity to thank the previous editors Drs. Jeff Zablocki and Carlos Garcia-Echeverria for their leadership in launching and defining this series. The high quality and range of contributions over the past 6 years have set a high bar and made this series a must-read section of the journal today. As a new decade launches, we are delighted to announce that Dr. Wendy B. Young, Senior Vice President, Genentech, will serve as the new Associate Editor for Drug Annotations. Dr. Young is the Senior Vice President for Small Molecule Drug Discovery at Genentech, where she leads a team of roughly 400 scientists (chemistry, biochemical pharmacology, drug metabolism and pharmacokinetics, pharmaceutical sciences) engaged in oncology, immunology, neuroscience, and infectious disease drug discovery and development. She has served as Chair of ACS MEDI, is an ACS Fellow, and is the recipient of the 2020 Earle B. Barnes Award for Leadership in Chemical Research. For Drug Annotations, a successful submission will highlight the full journey traveled by one discrete compound from its inception to progression into human clinical trials or approval. The manuscript should include information regarding target selection; hit identification; structure–activity relationships, including target potency, drug metabolism, and pharmacokinetics; pharmacology; and ideally, safety data. For compounds in early clinical development, human pharmacokinetic (PK) and initial clinical efficacy data are desirable but not essential to being accepted for publication. For compounds that are in pivotal trials or approved for marketing, clinical trial data and/or appropriate references should be included. Additionally, the author(s) should describe the goal of the program and the potential benefit to patients (e.g., first-in-class, best-in-class, and improvements over previous compounds). Please note that it is acceptable for pieces of the story to have been published previously, as the goal of Drug Annotations is to capture the complete story in one setting. From these stories, the medicinal chemistry community will have insights into the challenges overcome and the fine-tuning required to ensure a successful drug. For additional information on submissions, please refer to the guidelines for authors: http://pubsapp.acs.org/paragonplus/submission/jmcmar/jmcmar_authguide.pdf? We look forward to continuing growth of this truly exciting manuscript type under the leadership of Dr. Wendy Young. We also welcome any suggestions on stories you would like to read or how to make the Drug Annotations Series even more impactful and beneficial to our scientific community and the general public at large. Please send any suggestions for Drug Annotations to Dr. Wendy Young at [email protected]. Views expressed in this editorial are those of the authors and not necessarily the views of the ACS. This article has not yet been cited by other publications.

中文翻译：

---

新十年的药物注释。

《药品注释系列》于2014年推出，以案例研究的形式分享从实验室到临床开发的新药的故事。在《药品注释》中，读者关注影响人类健康的重要药物的药物化学历程。我们的目标是找出并发布这些故事，以指导和支持化学和药物发现界的成员，为患者寻求突破性的医学。自成立以来，《毒品注释系列》已成为展示此类案例研究的主要场所。在撰写本文时，已出版了55篇手稿，手稿涵盖了多种形式，包括小分子，蛋白质和抗体药物偶联物，仅举几例。我们想借此机会感谢以前的编辑Drs。Jeff Zablocki和Carlos Garcia-Echeverria在发起和定义该系列作品方面发挥了领导作用。在过去的6年中，高质量的论文和高质量的论文树立了很高的标准，并使该系列成为当今期刊必读的部分。在新的十年发布之际，我们很高兴地宣布，基因泰克高级副总裁Wendy B. Young博士将担任新的药物注释副编辑。Young博士是Genentech小分子药物发现部门的高级副总裁，她领导着由大约4​​00名科学家组成的团队（化学，生物化学药理学，药物代谢和药代动力学，药物科学），从事肿瘤学，免疫学，神经科学和传染病研究。药物发现与开发。她曾担任ACS MEDI主席，ACS研究员，并获得2020年Earle B.Barnes化学研究领导奖。对于药物注释，成功的提交将突出显示一种离散化合物从其开始到进入人体临床试验或批准的整个过程。手稿应包括有关目标选择的信息；命中识别 构效关系，包括靶标效力，药物代谢和药代动力学；药理; 最好是安全数据。对于处于早期临床开发阶段的化合物，人类药代动力学（PK）和初始临床功效数据是理想的，但对于被接受发表并不是必需的。对于正在进行关键性试验或批准用于市场的化合物，应包括临床试验数据和/或适当的参考文献。另外，作者应描述该计划的目标和对患者的潜在益处（例如，一流，一流和对以前化合物的改进）。请注意，故事的各个部分之前已发布是可以接受的，因为药物注释的目的是在一个环境中捕获完整的故事。从这些故事中，药物化学界将洞悉克服的挑战以及确保成功药物所需的微调。有关提交的其他信息，请参阅作者指南：http://pubsapp.acs.org/paragonplus/submission/jmcmar/jmcmar_authguide.pdf？我们期待在Wendy Young博士的领导下，这种真正令人兴奋的手稿类型继续发展。我们也欢迎您想阅读的故事方面的任何建议，或如何使《毒品注释系列》更具影响力，并对我们的科学界和广大公众有利。请将任何有关药物注释的建议发送给Wendy Young博士，地址为[电子邮件保护]。本社论中表达的观点只是作者的观点，不一定是ACS的观点。本文尚未被其他出版物引用。